Research notes from the team at DAAVY Research
Compound Brief breaks down sourcing, testing, documentation, and storage for laboratory researchers — what the paperwork actually means and what to check before you trust it.
Published by the team behind DAAVY Research, a research-peptide supplier. Where an article mentions DAAVY, it says so.
Email sign-ups are paused.
A preprint analyzed 6,285 third-party test reports on research peptides: 41.6% to 71.1% failed basic criteria, depending on the cutoff. What it can and cannot show.
Regulatory newsThe Federal Register notice is two pages. What it says, what sits in the appendices, the docket number and the comment window.
ToolMove the purity and content numbers, quiz yourself on what each report line answers, and check a report against two published cutoffs.
DocumentationEvery field on a real BPC-157 10 mg COA explained: dates, lot number, LC-MS/MS identity, content, HPLC purity, and what the report leaves out.
RegulatoryOn Oct 28, 2026 HHS announced temporary enforcement discretion for compounding six peptides. What the policy document requires, what it leaves open, and why.
Compound Brief is a free resource for laboratory researchers working with research peptides and compounds, published by the team behind DAAVY Research, a Texas-based supplier of research peptides. We write plain-language explainers on documentation, testing methods, and handling — the kind of thing that's usually buried in a PDF or a forum thread. Compound Brief is DAAVY Research's education site. DAAVY sells research peptides; some articles link to its pages. When an article mentions DAAVY, we say it's our own company.